keyword
MENU ▼
Read by QxMD icon Read
search

PEG-IFN

keyword
https://www.readbyqxmd.com/read/28637040/a-possible-role-of-therapeutic-drug-monitoring-in-virological-breakthrough-during-simeprevir-and-peg-ifn-treatment-in-hcv-4
#1
Lucio Boglione, Tina Ruggiero, Amedeo De Nicolò, Antonio D'Avolio, Giovanni Di Perri
No abstract text is available yet for this article.
June 22, 2017: Intervirology
https://www.readbyqxmd.com/read/28635613/association-of-the-s267f-variant-on-ntcp-gene-and-treatment-response-to-pegylated-interferon-in-patients-with-chronic-hepatitis-b-a-multicentre-study
#2
Kessarin Thanapirom, Sirinporn Suksawatamnuay, Wattana Sukeepaisarnjaroen, Sombat Treeprasertsuk, Tawesak Tanwandee, Phunchai Charatcharoenwitthaya, Satawat Thongsawat, Apinya Leerapun, Teerha Piratvisuth, Rattana Boonsirichan, Chalermrat Bunchorntavakul, Chaowalit Pattanasirigool, Bubpha Pornthisarn, Supoj Tuntipanichteerakul, Ekawee Sripariwuth, Woramon Jeamsripong, Teeranan Sanpanjit, Yong Poovorawan, Piyawat Komolmit
BACKGROUND: Sodium taurocholate co-transporting polypeptide (NTCP) is a cell receptor for hepatitis B virus (HBV). The S267F variant on the NTCP gene is inversely associated with the chronicity of HBV infection, progression to cirrhosis and hepatocellular carcinoma in East Asian populations. This aim of this study was to determine whether the S267F variant was associated with response to pegylated interferon (Peg-IFN) in patients with chronic HBV infection. METHODS: Two hundred and fifty-seven patients with chronic HBV, treated with Peg-IFN for 48 weeks, were identified from 13 tertiary hospitals included in the hepatitis B database of the Thai Association for the Study of the Liver (THASL)...
June 21, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28634723/combinational-use-of-hepatitis-b-viral-antigens-predicts-responses-to-nucleos-t-ide-analogue-peg-interferon-sequential-therapy
#3
Akihiro Matsumoto, Shuhei Nishiguchi, Hirayuki Enomoto, Jong-Hon Kang, Yasuhito Tanaka, Noboru Shinkai, Masayuki Kurosaki, Masaru Enomoto, Tatsuo Kanda, Osamu Yokosuka, Hiroshi Yatsuhashi, Shinya Nagaoka, Chiaki Okuse, Tatehiro Kagawa, Tetsuya Mine, Koichi Takaguchi, Satoru Saito, Keisuke Hino, Fusao Ikeda, Shotaro Sakisaka, Daisuke Morihara, Shiho Miyase, Masataka Tsuge, Kazuaki Chayama, Naoki Hiramatsu, Yoshiyuki Suzuki, Kazumoto Murata, Eiji Tanaka
BACKGROUND: This prospective cohort study searched for factors associated with a response to nucleos(t)ide analogue/peg-interferon (NUC/peg-IFN) sequential therapy. METHODS: A total of 95 patients with chronic hepatitis B being treated with NUCs were enrolled. Immediately following NUC cessation, peg-IFN was administered at 180 µg/dose weekly for 48 weeks. RESULTS: Twenty-six patients (27%) were judged to be responders at 48 weeks after the completion of peg-IFN...
June 20, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/28624460/identification-of-kx2-391-as-an-inhibitor-of-hbv-transcription-by-a-recombinant-hbv-based-screening-assay
#4
Keisuke Harada, Hironori Nishitsuji, Saneyuki Ujino, Kunitada Shimotohno
Antiviral therapies for chronic hepatitis B virus (HBV) infection that are currently applicable for clinical use are limited to nucleos(t)ide analogs targeting HBV polymerase activity and pegylated interferon alpha (PEG-IFN). Towards establishing an effective therapy for HBV related diseases, it is important to develop a new anti-HBV agent that suppresses and eradicates HBV. This study used recombinant HBV encoding NanoLuc to screen anti-HBV compounds from 1827 US Food and Drug Administration approved compounds and identified several compounds that suppressed HBV infection...
June 15, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28624102/hepatitis-e-virus-a-potential-threat-for-patients-with-liver-disease-and-liver-transplantation
#5
REVIEW
Annemiek A van der Eijk, Suzan D Pas, Robert A de Man
Immunocompromised patients are at risk of acquiring acute hepatitis E virus infection (HEV), leading to chronicity. Chronic HEV infection is associated with persistent viraemia, raised transaminase activity, histological features associated with chronic hepatitis and evidence of rapid development of cirrhosis. Extrahepatic manifestations have been associated with HEV. Most frequently reported are neurological disorders with predominantly involvement of the peripheral nervous system. In patients using immunosuppressive drugs antibody production is often delayed and HEV RNA detection is superior to serology to detect infection...
April 2017: Best Practice & Research. Clinical Gastroenterology
https://www.readbyqxmd.com/read/28611343/hbsag-clearance-in-chronic-hepatitis-b-patients-with-add-on-pegylated-interferon-alfa-2a-to-ongoing-tenofovir-treatment-a-randomized-controlled-study
#6
Hamad Al Ashgar, Musthafa C Peedikayil, Mohammed Al Quaiz, Fahad Al Sohaibani, Abdulrahman Al Fadda, Mohammed Q Khan, Einar Thoralsson, Sahar Al Thawadi, Ahmed Al Jedai, Khalid Al Kahtani
BACKGROUND/AIMS: The ideal end point of treatment for chronic hepatitis B virus (HBV) infection is sustained off-therapy hepatitis B surface antigen (HBsAg) loss with or even without seroconversion to anti-HBs. We investigated the role of adding PEGylated interferon (PEG IFN) to ongoing tenofovir treatment in chronic HBV patients for achieving HBsAg clearance. PATIENTS AND METHODS: In this randomized controlled trial, chronic HBV patients who have been receiving tenofovir for >6 months with HBV viral load <2000 IU/ml were randomized into two groups...
May 2017: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/28610605/adherence-to-response-guided-pegylated-interferon-and-ribavirin-for-people-who-inject-drugs-with-hepatitis-c-virus-genotype-2-3-infection-the-activate-study
#7
Evan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, Janaki Amin, Margaret Hellard, Graham R Foster, Philip Bruggmann, Brian Conway, Markus Backmund, Geert Robaeys, Tracy Swan, Philippa S Marks, Sophie Quiene, Tanya L Applegate, Martin Weltman, David Shaw, Adrian Dunlop, Julie Bruneau, Håvard Midgard, Stefan Bourgeois, Maria Christine Thurnheer, Gregory J Dore, Jason Grebely
BACKGROUND: The aims of this analysis were to investigate treatment completion and adherence among people with ongoing injecting drug use or receiving opioid substitution therapy (OST) in a study of response-guided therapy for chronic HCV genotypes 2/3 infection. METHODS: ACTIVATE was a multicenter clinical trial recruited between 2012 and 2014. Participants with genotypes 2/3 were treated with directly observed peg-interferon alfa-2b (PEG-IFN) and self-administered ribavirin for 12 (undetectable HCV RNA at week 4) or 24 weeks (detectable HCV RNA at week 4)...
June 13, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28557110/dose-escalation-study-evaluating-pegylated-interferon-alpha-2a-in-patients-with-cutaneous-t-cell-lymphoma
#8
M Schiller, A Tsianakas, W Sterry, R Dummer, A Hinke, D Nashan, R Stadler
BACKGROUND: This open-label, multicenter, dose-escalation study evaluated the safety, tolerability, and efficacy of subcutaneous pegylated (40 kD) interferon α-2a (PEG-IFN α-2a) in patients with cutaneous T-cell lymphoma (CTCL). PATIENTS AND METHODS: PEG-IFNα-2a was administered subcutaneously at 180 (n=4), 270 (n=6), or 360 μg (n=3) once weekly for 12 weeks. Efficacy was assessed by the proportion of patients with complete response (CR) or partial response (PR)...
May 30, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28554119/effectiveness-and-safety-of-ledipasvir-sofosbuvir%C3%A2-ribavirin-in-the-treatment-of-hcv-infection-the-real-world-harvest-study
#9
Robert Flisiak, Mariusz Łucejko, Włodzimierz Mazur, Ewa Janczewska, Hanna Berak, Krzysztof Tomasiewicz, Iwona Mozer-Lisewska, Dorota Kozielewicz, Andrzej Gietka, Katarzyna Sikorska, Marta Wawrzynowicz-Syczewska, Krzysztof Nowak, Dorota Zarębska-Michaluk, Joanna Musialik, Krzysztof Simon, Aleksander Garlicki, Robert Pleśniak, Barbara Baka-Ćwierz, Iwona Olszok, Krystyna Augustyniak, Wojciech Stolarz, Jolanta Białkowska, Anna Badurek, Anna Piekarska
BACKGROUND: To evaluate the effectiveness and safety of ledipasvir/sofosbuvir (LDV/SOF)±ribavirin (RBV) regimen in a real-world setting. METHODS: Patients received a fixed-dose combination tablet containing LDV and SOF with or without RBV, for 8, 12 or 24 weeks. Patients were assessed at baseline, end of treatment, and 12 weeks after the end of treatment. The primary effectiveness endpoint was sustained virologic response 12 weeks after the end of treatment (SVR12)...
May 26, 2017: Advances in Medical Sciences
https://www.readbyqxmd.com/read/28539950/association-of-changes-in-mood-status-and-psychosocial-well-being-with-depression-during-interferon-based-treatment-for-hepatitis-c
#10
Jung-Seok Choi, Won Kim, Bo Kyung Sohn, Jun-Young Lee, Hee Yeon Jung, Sohee Oh, Sae Kyoung Joo, Hwi Young Kim, Yong Jin Jung
OBJECTIVE: The aims of this prospective study were to investigate temporal changes in mood status and distress level, as well as the development of depression, during pegylated interferon (PEG-IFN)-based treatment of patients with chronic hepatitis C (CHC). We also explored whether baseline demographic, psychiatric, and personality traits predicted the evolution of depression. METHODS: CHC patients without depression were screened with laboratory tests; psychiatric interviews; and evaluations of mood symptoms, level of distress, and personality traits...
May 2017: Psychiatry Investigation
https://www.readbyqxmd.com/read/28539069/real-world-challenges-for-hepatitis-c-virus-medications-a-critical-overview
#11
Imran Shahid, Waleed Hassan AlMalki, Sajida Hassan, Muhammad Hassan Hafeez
From 2010, the landscape of hepatitis C therapeutics has been changed rapidly, and today we are standing at a cusp of a pharmacological revolution where highly effective and interferon (IFN)-free direct acting antivirals (DAAs) are already on the market. Such treatment paradigms attain 90-95% sustained virologic response (SVR; undetectable viral load at week 12 or 24 at the end of therapy) rates in treated individuals compared to 50-70% with treatment completion of dual-therapy-pegylated interferon (PEG-IFN) and ribavirin (RBV)...
May 25, 2017: Critical Reviews in Microbiology
https://www.readbyqxmd.com/read/28523305/the-impact-of-liver-steatosis-on-early-and-sustained-treatment-response-in-chronic-hepatitis-c-patients
#12
Alice Elena Găman, Anca Marilena Ungureanu, Adriana Turculeanu, Dan IonuŢ Gheonea, Andrei Ioan Drocaş, George Mitroi, Maria DobriŢoiu, Maria Victoria Comănescu, Andreea Doriana Stănculescu, Ramona Cioboată, Claudiu Florin Jieanu, Paul Ioan Tomescu
Steatosis is a frequent feature of hepatitis C virus (HCV) infection. Steatosis may be an important cofactor in both accelerating fibrosis and increasing liver necroinflammatory activity in chronic hepatitis C. The main objective of this study was the evaluation of biological response rates, early viral response, sustained viral response in patients with chronic hepatitis C treated with Interferon-alpha (IFN-α), Pegylated (PEG)-IFN-α2a or -α2b plus Ribavirin and to relate it to the presence of hepatic steatosis...
2017: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
https://www.readbyqxmd.com/read/28522204/peg-interferon-plus-nucleotide-analogue-treatment-versus-no-treatment-in-patients-with-chronic-hepatitis-b-with-a-low-viral-load-a-randomised-controlled-open-label-trial
#13
Annikki de Niet, Louis Jansen, Femke Stelma, Sophie B Willemse, Sjoerd D Kuiken, Sebastiaan Weijer, Carin M J van Nieuwkerk, Hans L Zaaijer, Richard Molenkamp, R Bart Takkenberg, Maarten Koot, Joanne Verheij, Ulrich Beuers, Hendrik W Reesink
BACKGROUND: Antiviral treatment is currently not recommended for patients with chronic hepatitis B with a low viral load. However, they might benefit from acquiring a functional cure (hepatitis B surface antigen [HBsAg] loss with or without formation of antibodies against hepatitis B surface antigen [anti-HBs]). We assessed HBsAg loss during peg-interferon-alfa-2a (peg-IFN) and nucleotide analogue combination therapy in patients with chronic hepatitis B with a low viral load. METHODS: In this randomised controlled, open-label trial, patients were enrolled from the Academic Medical Center (AMC), Amsterdam, Netherlands...
May 15, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28511425/early-experience-of-sofosbuvir-based-combination-therapy-in-real-life-cohort-with-chronic-hepatitis-c-infection
#14
Rajiv Mehta, Mayank Kabrawala, Subhash Nandwani, Rini Tekriwal, Payal Nandania
INTRODUCTION: There is scarcity of data in literature regarding the treatment response with Sofosbuvir (SOF) based therapy in Indian patients with chronic Hepatitis-C Virus (HCV) infection. AIM: This study was designed to observe initial treatment response to SOF based therapy in a "real-life" cohort of Indian patients with HCV infection. MATERIALS AND METHODS: This is a prospective, observational and single center study. A total of 107 patients who were diagnosed with chronic HCV infection and received SOF based treatment between March 2015 and December 2015 were included...
March 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28507928/the-role-of-direct-acting-antivirals-in-the-treatment-of-children-with-chronic-hepatitis-c
#15
REVIEW
Christine Hong Ting Yang, Eric R Yoo, Aijaz Ahmed
In the United States, chronic infection with the hepatitis C virus (HCV) affects an estimated 0.1-2% of the pediatric population, who are consequently at risk for major complications, including cirrhosis, hepatocellular carcinoma, and death. The current standard of treatment for chronic hepatitis C (CHC) in children is pegylated-interferon-alpha (PEG-IFN) in combination with ribavirin. PEG-IFN/ribavirin therapy is approved for children ages 3 and older; however, it is often held from use until adulthood because of its extensive list of potential side effects and high likelihood of causing adverse symptoms...
March 28, 2017: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/28506030/simeprevir-based-triple-therapy-with-reduced-doses-of-pegylated-interferon-%C3%AE-2a-plus-ribavirin-for-interferon-ineligible-patients-with-genotype-1b-hepatitis-c-virus
#16
Hideyuki Tamai, Yoshiyuki Ida, Akira Kawashima, Naoki Shingaki, Ryo Shimizu, Kosaku Moribata, Tetsushi Nasu, Takao Maekita, Mikitaka Iguchi, Jun Kato, Taisei Nakao, Masayuki Kitano
Background/Aims: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such as elderly and/or cirrhotic patients, and to elucidate the factors contributing to a sustained virologic response (SVR). Methods: One hundred IFN ineligible patients infected with genotype 1b hepatitis C virus (HCV) were treated. Simeprevir (100 mg) was given orally together with reduced doses of PEG-IFN-α 2a (90 μg), and ribavirin (200 mg less than the recommended dose)...
May 17, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28504854/the-risk-of-early-occurrence-and-recurrence-of-hepatocellular-carcinoma-in-hepatitis-c-infected-patients-treated-with-direct-acting-antivirals-with-and-without-pegylated-interferon-a-belgian-experience
#17
Bielen Rob, Christophe Moreno, Hans Van Vlierberghe, Stefan Bourgeois, Jean-Pierre Mulkay, Thomas Vanwolleghem, Wim Verlinden, Christian Brixco, Jochen Decaestecker, Chantal De Galocsy, Filip Janssens, Lode Van Overbeke, Christophe Van Steenkiste, Francois D'Heygere, Mike Cool, Katrien Wuyckens, Frederik Nevens, Geert Robaeys
Recently, concerns were raised of high rates of HCC recurrence in patients treated with direct acting antivirals (DAA) for hepatitis C infection. We investigated the HCC occurrence and recurrence rates within six months after treatment with DAA with or without Pegylated Interferon (PEG-IFN) in real life. This is a retrospective, multicenter cohort trial, executed in 15 hospitals distributed across Belgium. Populations were matched based on fibrosis score (Metavir F3-F4). Patients with a Child-Pugh score ≥ B were excluded...
May 15, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28497489/efficacy-and-safety-of-telaprevir-with-natural-human-interferon-beta-and-ribavirin-in-japanese-chronic-hepatitis-c-patients-with-depression
#18
Hiromitsu Kumada, Satoshi Mochida, Makoto Nakamuta, Fumitaka Suzuki, Takashi Yagi, Ryuji Takasaki, Masao Okai, Naohiro Kamiya, Yasushi Okada, Saya Hirota, Madori Orihashi, Miyoko Ochi, Kazuaki Chayama
AIMS: To assess the efficacy and safety of telaprevir (TVR) when used in combination with natural human interferon-beta (IFN-beta) and ribavirin (RBV) for the genotype 1 patients with depression as compared to the IFN-beta/RBV therapy in Japan. We also examined the efficacy of the TVR/IFN-beta/RBV therapy in treatment failure genotype 2 patients with depression. METHODS: For the genotype 1 patients, 30 patients received TVR (750 mg every 8 h) for 12 weeks combination with IFN-beta and RBV for 24 weeks (Group A), and 30 received IFN-beta and RBV for 48 weeks (Group B)...
May 11, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28487770/add-on-pegylated-interferon-alpha-2a-therapy-in-chronic-hepatitis-b-japanese-patients-treated-with-entecavir
#19
Hideyuki Tamai, Yoshiyuki Ida, Naoki Shingaki, Ryo Shimizu, Kazuhiro Fukatsu, Masahiro Itonaga, Takeichi Yoshida, Yoshimasa Maeda, Kosaku Moribata, Takao Maekita, Mikitaka Iguchi, Jun Kato, Masayuki Kitano
Entecavir requires long-term administration. Pegylated interferon (PEG-IFN) therapy leads to significant reduction of hepatitis B surface antigen (HBs Ag) levels. This study aimed to assess the safety and efficacy of adding PEG-IFN-α-2a to entecavir toward cessation of entecavir. A total of 23 patients treated with entecavir underwent add-on PEG-IFN-α-2a therapy (90 μg per week) for 48 weeks. Viral response (VR) was defined as more than 50% reduction of baseline hepatitis B surface antigen (HBs Ag) level at 72 weeks from the start of therapy...
2017: Hepatitis Research and Treatment
https://www.readbyqxmd.com/read/28482405/-efficacy-and-safety-of-pegylated-interferon-%C3%AE-2b-injection-y-shape-40-kd-in-treatment-of-patients-with-genotype-1-6-chronic-hepatitis-c
#20
B Feng, J Shang, S H Wu, H Chen, Y Han, Y Q Li, D Z Zhang, L F Zhao, S F Wei, Q Mao, C B Yin, T Han, M R Wang, S J Chen, J Li, Q Xie, Z Zhen, Z L Gao, Y X Zhang, G Z Gong, D L Yang, C Pan, J F Sheng, H Tang, Q Ning, G F Shi, J Q Niu, G H Luo, Y T Sun, H You, G Q Wang, L L Zhang, J Peng, Q Zhang, J J Liu, C W Chen, X Y Chen, W Zhao, R H Wang, L Sun, L Wei
Objective: To investigate the efficacy and safety of the new investigational drug pegylated interferon α-2b (Peg-IFN-α-2b) (Y shape, 40 kD) injection (180 µg/week) combined with ribavirin in the treatment of patients with genotype 1/6 chronic hepatitis C (CHC), with standard-dose Peg-IFN-α-2a combined with ribavirin as a positive control. Methods: A multicenter, randomized, open-label, and positive-controlled phase III clinical trial was performed. Eligible patients with genotype 1/6 CHC were screened out and randomly divided into Peg-IFN-α-2b(Y shape, 40kD) group and Peg-IFN-α-2a group at a ratio of 2:1...
March 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
keyword
keyword
31627
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"